• A bill would allow NIH to establish a $400m private fund for rare diseases

    Pharmalot |  Two Congressmen have introduced a bill for an R&D Fund that would allow the NIH to serve as an advisor for a $400m pot raised from private investors. The fund could resemble a hybrid between a public-private partnership and a venture capital vehicle.

    Oct 15, 2015

  • 21st Century Cures Act Steeped in Controversy

    Clinical Informatics News | In a dazzling display of bipartisanship, the United States (US) House of Representatives passed the 21st Century Cures Act (“Act”) on July 10, 2015, by a wide margin. But outside of the Capitol, the Act has evoked both positive and negative reaction.

    Oct 14, 2015

  • Why the FDA should take more chances on riskier drugs

    Pharmalot |  An MIT study challenges the FDA to be more flexible in drug approvals, altering the odds based on the severity of the disease and availability of treatments.

    Oct 6, 2015

  • Sidra Medical Center Deploys NextCODE for Qatar Genome Project

    Clinical Informatics News | WuXi NextCODE today announced a long-term agreement with Sidra Medical and Research Center in Qatar. The two groups plan to co-develop comprehensive research and bioinformatics programs that will link with the Qatari national electronic medical record system.

    Oct 5, 2015

  • The story of AllTrials

    AllTrials |  In May, Trevor Butterworth, Director of Sense About Science USA, interviewed Ben Goldacre and Síle Lane to talk about the history of the AllTrials campaign. Here's a transcript of that interview.

    Oct 2, 2015

  • September Clinical News and Product Briefs

    Clinical Informatics News | Clinical news and product releases from around the industry, including an electronic health monitoring partnership between a pharmacy and senior center, and an app for comparing medication prices.

    Sep 30, 2015

  • The Non-Negotiable Cost of Drugs

    Clinical Informatics News | Contributed Commentary | This month’s controversy surrounding Turing Pharmaceutical’s CEO Martin Shkreli’s attempt to raise the price of Daraprim by more than 5,000% was met with such outrage from payers, patients and pundits Shrkeli was forced to back off the increase. The Daraprim episode is the latest and most striking in the new “war on drugs.” The war is no longer defined as an offensive against illegal narcotics, but one against pharmaceutical companies and the increasing costs of specialty drugs.

    Sep 29, 2015

  • Cycle Times Increasing Thanks to Start-Up Lag

    Clinical Informatics News | Despite a trend toward shorter clinical trial cycle times, recent data analysis asserts that Phase II/III cycles have actually increased.

    Sep 24, 2015

  • The Life of a Clinical-Trial Guinea Pig

    The Atlantic |  What it's like to earn a living as a research subject in clinical trials.

    Sep 23, 2015

  • Will IBM’s Watson Identify Patients For Your Next Trial

    Clinical Leader |  Will ICON and IBM succeed in revolutionizing clinical trial recruitment and start-up times? Both companies certainly hope so. Last week the two announced they are working together to connect patients to relevant clinical trials.

    Sep 16, 2015